In KA-induced TLE mice, GPR120 peaked at 7 days post-KA in hippocampus and cortex and colocalized almost exclusively with NeuN+ neurons (89% CA1, 96% CA3, 80% cortex), not GFAP+ astrocytes or Iba1+ microglia . AAV-mediated knockdown (58% efficiency) vs overexpression (166%) produced bidirectional seizure effects with n=6 per group:
Overexpression also reduced seizure-like events in 30-min LFP windows (11.18Β±1.05 vs 22.00Β±1.05 in Con-OE) and total SLE time (157.2Β±28.42 vs 388.6Β±47.26 s), while single-event duration did not differ .
GPR120 manipulation tracked NLRP3 inflammasome components and cytokines in parallel; VX765 (Caspase-1 inhibitor) rescued KD-induced IL-1Ξ²/IL-18 elevation and neuronal death but not IL-6, consistent with NLRP3 specificity yet also limiting the pathway claim to IL-1Ξ²/IL-18 arms .
Strengths: Bidirectional manipulation (KD + OE), behavioral + electrophysiological + histological + molecular readouts, randomization/blinding stated, and a pharmacological rescue anchoring causality. Notably, the paper itself addresses sex bias partially by acknowledging scope but used only male mice.
Blindspots: n=3 for Nissl analyses limits power; some reported values appear internally inconsistent (e.g., Con-KD CA1 given as 55.00Β±4.73 vs 55.20Β±5.67 for Con-OE in different passages). The claim that GPR120 is "a ligand of NLRP3" is an overreachβno direct binding data exist; the evidence supports pathway co-regulation only. No GPR120 antagonist/agonist control group, no direct NLRP3 knockout comparison, and no ASC speck or pyroptosis (GSDMD) assaysβso "NLRP3 activation" is inferred from protein abundance, not inflammasome assembly. The internalization mechanism is imported from hepatic/Kupffer-cell work rather than demonstrated here . Cell-type data conflict with hypothalamic mapping where GPR120 is microglial, not neuronal .
What would change the conclusion: Direct NLRP3 genetic loss-of-function failing to phenocopy VX765 rescue, or lack of replication in female mice or alternative epilepsy models (pilocarpine, kindling) would undermine the pathway claim. External validity to human TLE remains untested.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.